This post was originally published on News-medical.net
You will shortly be re-directed to the publisher's website
A clinical trial testing muvalaplin, a novel oral medication, was able to safely and effectively lower high levels of lipoprotein (a), according to late-breaking science presented today at the American Heart Association’s Scientific Sessions 2024.